TEVA - Corcept Therapeutics Stock Merits Accumulation
2024-06-11 12:08:45 ET
Summary
- Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents.
- However, the company is preparing an NDA for Korlym's successor, which could be approved for all etiologies of Cushing's syndrome.
- Corcept also has multiple clinical trials readouts expected in 2024 and a strong balance sheet, making it the stock worthy of accumulation.
- An updated analysis around Corcept Therapeutics follows in the paragraphs below.
Shares of cortisol concern Corcept Therapeutics Incorporated ( CORT ) were initially suppressed after a court found that Teva’s ((TEVA)) generic would not infringe on its Korlym’s (mifepristone) patents. The shares have acted much better recently, it should be noted. This has prompted a revisit since our last article on this name almost four months ago....
Corcept Therapeutics Stock Merits Accumulation